Abstracts

IMMUNOLOGICAL AND GLYCOMIC CORRELATES OF TIME-TO-HIV-REBOUND IN VIREMIC CONTROLLERS

Analytic treatment interruption (ATI) is the most reliable way to evaluate the efficacy of potential HIV cure strategies but require lengthy and intensive monitoring. Identifying pre-ATI correlates of time-to-HIV-rebound (TTHR) after antiretroviral therapy (ART) cessation can significantly aid the development of a functional cure to HIV infection. We examined the associations between TTHR and pre-ATI…

HIV ENVELOPE DIVERSITY AND SENSITIVITY TO bNAbs ACROSS STAGES OF ACUTE AND EARLY HIV

Genetic diversity of the HIV envelope (env) complicates use of broadly neutralizing antibodies (bNAbs) for HIV treatment and cure. Antiretroviral therapy (ART) during acute or early HIV infection (AEHI) restricts reservoir size and diversity, increasing the likelihood of bNAb susceptibility. Successful treatment of ART-suppressed patients with bNAbs requires understanding the evolution of env diversity. We…

FUNCTIONAL MDSCs ARE MAINTAINED DURING ART AND PRECLUDE HIV-1 RESERVOIR REACTIVATION

In the past years, new therapeutic strategies aimed to deplete the HIV-latent infection by inducing viral reactivation have not been successful in vivo. The inability to reactivate and/or eliminate all HIV-infected cells could be explained by the presence of immune-regulatory mechanisms that inhibit viral reactivation and anti-HIV immune effector cells. We hypothesize that HIV reactivation…

EFFICACY OF Ad26/MVA + Env + VESATOLIMOD THERAPEUTIC VACCINATION IN RHESUS MACAQUES

Recent work assessing the immunogenicity and efficacy of therapeutic vaccination in SIV/SHIV infected rhesus macaques while on antiretroviral therapy (ART) has shown promise. We asked whether modifying a current adenovirus serotype 26 (Ad26) and modified vaccinia Ankara (MVA) therapeutic prime boost regimen expressing SIV Gag, Pol, and Env, in combination with the TLR7 agonist vesatolimod…

BEAT2: PEG-IFN-?2B + 3BNC117 AND 10-1074 KEEPS HIV AT

Broadly neutralizing anti-HIV monoclonal antibodies (bNAbs) have shown promising results for the prevention and treatment of HIV. We present the results of Step 3 of BEAT2 evaluating whether the combination of bNAbs 3BNC117 and 10-1074 plus peg-IFN-?2b can prevent or delay the return of viremia during 26 weeks of ART interruption (ATI). BEAT2 (NCT03588715) is…

INDUCIBLE RESERVOIR IN TISSUES, BUT NOT IN PERIPHERY, PREDICTS FUNCTIONAL CURE OF SIV

HIV persistence in reservoirs requires lifelong antiretroviral therapy (ART), calling for cure. Latency reversing agents (LRAs), such as the histone deacetylase inhibitor romidepsin, reactivate and clear HIV/SIV through cell-mediated immune responses and viral lytic effects (‘shock and kill’). We tested a total of four single infusions and two ‘double infusions’ (two infusions separated by 48…